Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma

National Cancer Institute. Cancer stat facts: kidney and renal pelvis cancer. https://seer.cancer.gov/statfacts/html/kidrp.html. Dabestani, 2016, Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study, World J Urol, 34, 1081, 10.1007/s00345-016-1773-y Dudani, 2021, Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival, JAMA Netw Open, 4, e2021869, 10.1001/jamanetworkopen.2020.21869 Ljungberg, 2019, European Association of Urology guidelines on renal cell carcinoma: the 2019 update, Eur Urol, 75, 799, 10.1016/j.eururo.2019.02.011 National Comprehensive Cancer Network, 2021 Grunwald, 2018, An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma, Nat Rev Urol, 15, 511, 10.1038/s41585-018-0034-9 Vogel, 2019, Imaging in suspected renal-cell carcinoma: systematic review, Clin Genitourin Cancer, 17, e345, 10.1016/j.clgc.2018.07.024 Capogrosso, 2016, Follow-up after treatment for renal cell carcinoma: the evidence beyond the guidelines, Eur Urol Focus, 1, 272, 10.1016/j.euf.2015.04.001 Alongi, 2016, Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT, Eur J Nucl Med Mol Imaging, 43, 464, 10.1007/s00259-015-3159-6 Silver, 1997, Prostate-specific membrane antigen expression in normal and malignant human tissues, Clin Cancer Res, 3, 81 Perera, 2020, Eur Urol, 77, 403, 10.1016/j.eururo.2019.01.049 Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7 Siva, 2020, Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer, Nat Rev Urol, 17, 107, 10.1038/s41585-019-0272-5 Chang, 1999, Prostate-specific membrane antigen is produced in tumor-associated neovasculature, Clin Cancer Res, 5, 2674 Ahn, 2019, A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC), Mol Imaging Biol, 21, 799, 10.1007/s11307-018-01307-0 Siva, 2017, Utility of 68Ga prostate specific membrane antigen-positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma, J Med Imaging Radiat Oncol, 61, 372, 10.1111/1754-9485.12590 Evangelista, 2020, The Role of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography for the evaluation of renal cancer, Eur Urol Focus, 6, 146, 10.1016/j.euf.2018.08.004 Siva, 2013, 18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience, J Nucl Med, 54, 1223, 10.2967/jnumed.112.116814 Barber, 2012, 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data, J Nucl Med, 53, 864, 10.2967/jnumed.111.101568 Hicks, 2001, The utility of 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification, J Nucl Med, 42, 1605 R Core Team, 2019 Raveenthiran, 2019, The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma, Eur J Nucl Med Mol Imaging, 46, 2280, 10.1007/s00259-019-04432-2 Rhee, 2016, Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour, EJNMMI Res, 6, 76, 10.1186/s13550-016-0231-6 Meyer, 2019, Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT, Ann Nucl Med, 33, 617, 10.1007/s12149-019-01371-8 Rowe, 2015, Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT, Ann Nucl Med, 29, 877, 10.1007/s12149-015-1017-z Gorin, 2017, PSMA-targeted 18F-DCFPyL PET/CT imaging of clear cell renal cell carcinoma: results from a rapid autopsy, Eur Urol, 71, 145, 10.1016/j.eururo.2016.06.019 Sawicki, 2017, Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience, Eur J Nucl Med Mol Imaging, 44, 102, 10.1007/s00259-016-3360-2 Gao, 2021, Comprehensive evaluation of 68Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma, Eur J Nucl Med Mol Imaging, 48, 561, 10.1007/s00259-020-04916-6 Hofman, 2021, [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial, Lancet, 397, 797, 10.1016/S0140-6736(21)00237-3 Sartor, 2021, Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer, N Engl J Med, 385, 1091, 10.1056/NEJMoa2107322 Uijen, 2021, PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports, Eur J Nucl Med Mol Imaging, 48, 4350, 10.1007/s00259-021-05433-w Liu, 2020, Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients, Nucl Med Commun, 41, 1299, 10.1097/MNM.0000000000001285 Baccala, 2007, Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms, Urology, 70, 385, 10.1016/j.urology.2007.03.025 Spatz, 2018, Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role, J Urol, 199, 370, 10.1016/j.juro.2017.08.079 Al-Ahmadie, 2008, Expression of prostate-specific membrane antigen in renal cortical tumors, Mod Pathol, 21, 727, 10.1038/modpathol.2008.42 Yin, 2019, Inconsistent detection of sites of metastatic non-clear cell renal cell carcinoma with PSMA-targeted [18F]DCFPyL PET/CT, Mol Imaging Biol, 21, 567, 10.1007/s11307-018-1271-2 Mittlmeier, 2021, 18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results, Eur J Nucl Med Mol Imaging, 48, 2031, 10.1007/s00259-020-05165-3 Gühne, 2021, PSMA-PET/CT in patients with recurrent clear cell renal cell carcinoma: histopathological correlations of imaging findings, Diagnostics, 11, 1142, 10.3390/diagnostics11071142 Golan, 2021, Dynamic 68Ga-PSMA-11 PET/CT for the primary evaluation of localized renal mass: a prospective study, J Nucl Med, 62, 773, 10.2967/jnumed.120.251272 Tariq, 2022, The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: a multi-institutional case series with intra-individual comparison, Urol Oncol, 40, 66.e1, 10.1016/j.urolonc.2021.11.006 Meng L, Zhang S, Gao J, et al. [68Ga]Ga-PSMA-11 PET/CT has potential application in predicting tumor HIF-2α expression and therapeutic response to HIF-2α antagonists in patients with RCC. Eur Radiol. In press. https://doi.org/10.1007/s00330-022-08738-y. Tariq, 2022, Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT), Urol Oncol, 40, 276.e1, 10.1016/j.urolonc.2022.03.007